We therefore hypothesized that BMP3 expression may be reduced in biliary cancers, resulting in a lack of tumor suppressor function due to aberrant BMP3 promoter methylation, and that methylated BMP3 may serve as a clinically useful biomarker in these cancers. The gene discussed is BMP3; the disease is neoplasm.